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Rationale: The mechanisms of airway hyper-responsiveness are only partially understood and
the contribution of airway remodelling is unknown. Airway remodelling can be assessed by
measuring airway distensibility, which is reduced in asthma, even when lung function is
normal. We hypothesised that airway remodelling contributes to airway hyper-
responsiveness in asthma, independent of steroid-responsive airway inflammation.
Objectives: To determine the relationship between airway distensibility and airway respon-
siveness at baseline and after 12 weeks of inhaled corticosteroid therapy in a group of asth-
matics with airway hyper-responsiveness.
Methods: Nineteen doctor-diagnosed asthmatics had airway distensibility measured as the
slope of the relationship between conductance and lung volume by the forced oscillation tech-
nique. Lung function, exhaled nitric oxide and methacholine challenge were also measured.
Subjects had inhaled corticosteroid therapy for 12 weeks after which all measurements were
repeated.
Results: At baseline, airway distensibility (mean, 95%CI) was 0.19(0.14e0.23) cm H2O
1 s1,
exhaled nitric oxide was 13.1(10.3e16.6) ppb and airway distensibility correlated with eNO
(pZ 0.04) and disease duration (pZ 0.02) but not with airway responsiveness (pZ 0.46),
FEV1 (pZ 0.09) or age (pZ 0.23). After treatment, exhaled nitric oxide decreased
(pZ 0.0002), FEV1 improved (pZ 0.0001), airway responsiveness improved (pZ 0.0002),
and there was a small improvement in airway distensibility but it did not normalisestitute of Medical Research, PO Box M77, Missenden Road, NSW 2050, Australia. Tel.: þ61 2 9114 0146;
lcock.org.au (J.A. Kermode).
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Airway remodelling on airway hyper-responsiveness 1799(pZ 0.05). Airway distensibility was not correlated with either exhaled nitric oxide (pZ 0.49)
or airway responsiveness (pZ 0.20).
Conclusions: Uncontrolled airway inflammation causes a small decrease in the distensibility of
the airways of asthmatics with airway hyper-responsiveness. The lack of association between
airway responsiveness and airway distensibility, both before and after 12 weeks ICS treatment,
suggests that airway remodelling does not contribute to airway hyper-responsiveness in
asthma.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
The mechanisms of airway hyper-responsiveness (AHR),
which is a distinguishing feature of asthma, are only
partially understood. The airways in patients with asthma
are characterised by the presence of airway inflammation
and/or airway remodelling. Airway inflammation is clearly
associated with AHR, since AHR correlates with markers of
inflammation1 and improves with anti-inflammatory
treatment.2e6 The contribution of airway remodelling to
AHR is unknown, yet is the subject of much debate, with
current hypotheses ranging from airway remodelling
enhancing airway responsiveness7e10 to airway remodelling
protecting against AHR.9,11,12
Airway remodelling can be assessed by measuring airway
distensibility, which is reduced in asthma, even when lung
function is normal,11,13e17 and is associated with thickening
of the reticular basement membrane layer of the airway
wall.16 The potential effects of remodelling on both the
geometry (increased wall thickness) and mechanical prop-
erties (increased stiffness) of the airways are likely to
result in irreversible airway narrowing and a reduction in
the effects of deep inspirations, which modulate airway
smooth muscle (ASM) contractility, with subsequent
increases in AHR. An alternative proposal is that increased
extracellular matrix and airway wall thickening could
decrease airway compressibility, which may in turn be
protective against AHR.9
To understand the contribution of airway remodelling to
AHR the effects of inflammation on airway distensibility,
the marker of remodelling, must be determined. The acute
airway inflammatory response, consisting of an influx of
inflammatory cells, mucus hypersecretion, and microvas-
cular leakage leading to oedema,18 could thicken the
airways thereby contributing to reduced airway distensi-
bility. While short-term inhaled corticosteroid (ICS) treat-
ment up to 12 weeks appears insufficient to alter
remodelling, measured by reticular basement membrane
thickness,6 it can effectively reduce both airway wall
thickness, measured by high resolution computed tomog-
raphy (HRCT),19 and inflammation, measured either by
bronchiolar lavage,2,5 bronchial biopsy,2e4,6 or exhaled
nitric oxide (eNO).4 The effects of ICS on markers of airway
remodelling require longer-term treatment of 6e12
months.6 These differences in the time courses of response
to ICS of the inflammatory and airway remodelling
components of asthma can be exploited to determine the
contribution of airway remodelling to AHR, since after
treating steroid-responsive inflammation with relatively
short-term ICS, any remaining association between airwaydistensibility and AHR is likely to be due to the effects of
airway remodelling.
We hypothesised that airway remodelling contributes to
AHR in asthma, independent of steroid-responsive airway
inflammation. Our specific aim was to determine the rela-
tionship between airway distensibility and airway respon-
siveness at baseline and after 12 weeks of inhaled
corticosteroid therapy in a group of asthmatics with AHR.
Methods
Study subjects
Nineteen adults (9 males) with asthma were recruited by
advertisements at The Woolcock Institute of Medical
Research, The University of Sydney, and The Respiratory
Clinic at Royal North Shore Hospital. Inclusion criteria were
physician diagnosis of asthma plus either current symptoms
or current treatment and airway hyper-responsiveness to
methacholine. Subjects were excluded if they were current
smokers, or had quit smoking within the previous six months,
had a smoking history >10 pack years, had another respira-
tory or major illness, used oral prednisone or had a respira-
tory tract infection in the last month. All subjects provided
written informed consent. The study was approved by the
Human Ethics committee of the Sydney South West Area
Health Service and the Northern Sydney Central Coast
Health Service. The study was registered on the Australian
Clinical Trials Registry (ACTRN12610000561088).
Study design
All subjects had a series of tests performed on a single visit
to the laboratory after which they underwent 12 weeks of
treatment with fluticasone proprionate/salmeterol xina-
foate 250/25 ug MDI 2 puffs bd via spacer. Following
treatment, all measurements were repeated at a second
visit. Short- and long-acting bronchodilator medications
were withheld prior to each visit for at least 6 and 24 h,
respectively. Asthma severity was based on the GINA
guidelines.20
Methods
Subjects completed a respiratory health questionnaire, the
Asthma Control Questionnaire (ACQ),21 had allergen skin-
prick tests, spirometry and whole body plethysmography
using a Medisoft BodyBox 5500 (Medisoft Corporation, Sorr-
ines, Belgium). Exhaled nitric oxide (eNO) was measured
1800 J.A. Kermode et al.using an offline technique22 at 200 ml/s according to Amer-
ican Thoracic Society guidelines.23
Airway distensibility was measured by the forced oscil-
lation technique24 and calculated as the slope of conduc-
tance (Grs) versus lung volume between 75% total lung
capacity (TLC) and TLC. All subjects performed the
following breathing protocol: 1 min of stable tidal breathing
followed by a slow inhalation to TLC then another minute of
tidal breathing. Subjects then inhaled slowly to TLC and
breathed at approximately tidal volumes with progressively
decreasing end-expiratory lung volumes until end expira-
tion was near FRC, and tidal breathing was resumed. This
deflation manoeuvre was performed twice after which the
subject slowly inhaled to TLC to complete the test. Abso-
lute lung volumes were calculated by referencing the
maximal inhalations to plethysmographic TLC. Airway
distensibility was calculated from Grs and lung volume data
at points of zero flow (end inspiration and end expiration).
The combined data from all deflation manoeuvres were
used to plot Grs against lung volume and then the linear
least-squares slope of Grs vs. lung volume between 75% TLC
and TLC was calculated to give the index of airway
distensibility. Although the previous study used two linear
functions to describe the Grselung volume relationship:
FRC to 75% TLC and 75% TLC to TLC, only the 75% TLC to TLC
function discriminated between asthmatic and non-
asthmatic subjects. Furthermore, airway distensibility
between 75% TLC and TLC accounts for approximately 80%
of total airway distensibility in both non-asthmatic and
asthmatic subjects.24 Therefore, in the current study, we
only report airway distensibility between 75% TLC and TLC.
Mean airway distensibilty in non-asthmatic adults is
0.44 0.08.24
Subjects had AHR measured by methacholine challenge25
and defined as a PD20FEV1< 6.1 mmol methacholine.
Responsiveness to methacholine was also measured on
a continuous scale as the dose response slope (DRS).26 The
DRS was calculated as % fall in FEV1/mmol methacholine and
a constant of 3 was added to allow for log transformation of
zero or negative values. This allowed the inclusion of data
from subjects who had a fall in FEV1 of <20% either at
baseline or after treatment. In terms of the continuous
measure, AHR is defined as a DRS of>3.27% fall in FEV1/mmol
methacholine, which is equivalent to a PD20FEV1< 6.1 mmol
methacholine.Analysis
Data were analysed using Analyse-It for Microsoft Excel
software (Analyse-It Software Ltd, Leeds, UK) and the SAS
system (SAS Institute, Inc., Cary, NC). DRS and eNO were
log-normally distributed and were log10 transformed for all
analyses. The relationships between AHR (expressed as
DRS), inflammation (expressed as eNO) and airway disten-
sibility were examined by performing univariate (Pearson)
correlations. Multiple linear regression analyses were used
to examine the predictors of baseline airway distensibility,
airway distensibility after treatment, and the change in
airway distensibility with treatment. The independent
predictors included in the models were: FEV1 (baseline,
after treatment, or change in FEV1with treatment), eNO(baseline, after treatment, or change in eNO with treat-
ment) and ICS use, disease duration, age, height and
weight. For categorical variables, data are expressed as
number and percent of group, and analysed by the Chi-
squared test. Data are shown as means with 95% confi-
dence intervals (CI) unless otherwise specified. p Values <
0.05 were considered statistically significant.
Results
The individual characteristics of the subjects are shown in
Table 1. The subjects were adults with mild- to moderate-
persistent asthma,20 and disease durations ranging from 1
to 53 years (Table 1). In these subjects airway distensibility
was less than previously observed in non-asthmatics, and
similar to that measured in mild to moderate asthmatics24
(Table 1). Current inflammation was mild in this group, as
shown by the relatively low eNO (Table 1).
At baseline, airway distensibility correlated with eNO
(rZ 0.47, pZ 0.04) and disease duration (rZ0.52,
pZ 0.02) but not with DRS (rZ0.18, pZ 0.46), FEV1
(rZ 0.40, pZ 0.09) or age (rZ0.29, pZ 0.23). Smoking
history was negligible, as there were only 2 ex-smokers with
10 and 1.05 pack years, respectively.
Table 2 shows the effects of 12 weeks treatment with
combination therapy on key outcome measures. As expec-
ted the treatment reduced eNO by 46% (pZ 0.0002) and
improved FEV1 (pZ 0.0001), DRS (p< 0.0001) and ACQ
(pZ 0.0009). There was a small improvement of
0.06 cmH2O s
1 (pZ 0.05) in airway distensibility following
treatment (see Fig. 1). After treatment, there were no
correlations between airway distensibility and either eNO
(rZ0.18, pZ 0.49), DRS (rZ0.31, pZ 0.20, see
Fig. 2), FEV1 (rZ 0.28, pZ 0.24) or age (rZ0.14,
pZ 0.58).
The multiple regression analyses confirmed these
results. At baseline, eNO and duration of asthma were
predictors of airway distensibility, independent of prior ICS
use, FEV1, age height and weight (model R
2Z 0.51,
pZ 0.004). There were no independent predictors of
airway distensibility after treatment or of the change in
airway distensibilty with treatment.
Discussion
In this study of patients with asthma, defined by the pres-
ence of airway hyper-responsiveness to methacholine, we
found that airway distensibility correlated with eNO at
baseline and that there was a small, borderline significant
change in airway distensibility after 12 weeks of ICS
treatment. These results suggest that steroid-responsive
airway inflammation causes a small decrease in the
distensibility of the airways of asthmatic subjects with
AHR. After treatment, and despite the small improvement,
airway distensibility remained abnormal and there was no
correlation between airway distensibility and eNO, which
suggests that the remaining abnormalities in airway
distensibility are not due to steroid-responsive airway
inflammation. These remaining abnormalities in airway
distensibility are most likely due to airway remodelling. We
also found that there was no correlation between airway


















1 55 20.2 34 67.07 0.81 0.03 0.60 2.57 1000 7.10
2 27 34.3 26 116.82 0.64 0.25 0.40 1.71 250 14.30
3 25 19.5 18 71.04 0.56 0.19 0.59 1.71 0 23.40
4 32 25.9 28 87.49 0.57 0.42 0.51 1.00 0 25.80
5 54 22.7 53 85.36 0.67 0.10 1.96 1.29 500 19.90
6 30 30.6 29 97.47 0.57 0.23 0.79 0.29 0 12.75
7 23 27.0 19 102.80 0.71 0.20 5.24 1.29 0 11.60
8 37 34.5 34 55.83 0.56 0.06 0.16 2.14 1000 6.00
9 26 22.8 16 99.95 0.68 0.22 0.78 0.71 0 24.85
10 46 29.1 36 63.41 0.51 0.12 0.37 2.14 500 21.25
11 40 30.6 39 81.46 0.52 0.10 0.13 2.29 500 7.55
12 20 22.4 17 109.85 0.86 0.28 5.08 0.00 0 22.35
13 29 27.3 24 73.07 0.62 0.35 0.21 1.71 0 23.10
14 59 25.4 34 78.75 0.54 0.09 0.47 0.85 0 7.00
15 23 22.4 20 91.32 0.79 0.14 1.18 1.14 250 7.05
16 35 23.4 30 73.55 0.54 0.16 0.14 0.57 0 10.70
17 62 27.4 1 79.41 0.68 0.33 0.89 0.71 250 6.40
18 24 22.6 23 95.80 0.66 0.08 0.15 1.57 0 18.25
19 45 25.8 10 84.76 0.48 0.20 0.27 1.00 0 11.90
Data are presented as mean 95% CI unless otherwise stated. FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ppb,
parts per billion; DRS, dose response slope; eNO, exhaled nitric oxide; ACQ, Asthma Control Questionnaire; BDP, beclomethasone
dipropionate; BMI, body mass index; and PD20FEV1, provocative dose of methacholine inducing a 20% fall in FEV1.
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after treatment, which suggests that airway remodelling
does not contribute to AHR in asthma, independent of
steroid-responsive airway inflammation.
We used an appropriate population of well-defined
asthmatics, which allowed us to detect the effects of
inflammation on all of the main outcome measuresTable 2 Subject characteristics.
Parameter Baseline
Age, years (range) 36.4 (20e62)
BMI, kg/m2 26.0 (24.0e28
Duration, years (range) 25.8 (1e53)
FEV1, % predicted 74.9 (67.2e82
FVC, % predicted 95.3 (88.3e10
FEV1/FVC 0.6 (0.6e0.7
Airway distensibilitya, cm H2O
1 s1 0.19 (0.14e0.
eNOb, ppb 13.1 (10.3e16
DRSb, % fall FEV1/mmol methacholine 35.4 (22.9e54
ACQ 1.3 (1.0e1.6
BDP equivalent dose, mg/day 236.1 (80.3e39
ICS, % using 42.1
RV, % predicted 147.8 (127.2e1
FRC, % predicted 121.1 (109.0e1
TLC, % predicted 115.5 (109.2e1
Data are presented as mean 95% CI unless otherwise stated.
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; TLC
slope; eNO, exhaled nitric oxide; ACQ, Asthma Control Questionna
corticosteroid treatment; RV, residual volume; BDP, beclomethasone
a Mean in normalsZ 0.44 0.08.
b Geometric mean.including airway distensibility. The subjects in the study
were selected because they had AHR and were likely to
respond to anti-inflammatory treatment because of either
poor ACQ or high eNO. The group also had reduced airway
distensibility at baseline.24 The baseline relationship
between eNO and airway distensibility suggests that airway
inflammation contributes to reduced airway distensibility,After treatment p
.0)
.6) 85.0 (77.8e92.3) 0.0001
2.3) 100.3 (93.7e107.0) 0.02
) 0.7 (0.6e0.7) <0.0001
23) 0.24 (0.20e0.29) 0.05
.6) 7.1 (6.2e8.1) 0.0002
.8) 9.7 (6.1e15.4) <0.0001
) 0.7 (0.4e1.0) 0.0009
1.9) 2000
100
68.5) 129.1 (114.4e143.8) 0.04
33.2) 117.7 (107.5e127.8) 0.26
21.8) 114.6 (108.2e121.1) 0.25
, total lung capacity; ppb, parts per billion; DRS, dose response
ire; FRC, functional residual capacity; ICS, patients on inhaled
dipropionate; and BMI, body mass index.
Figure 1 Airway distensibility was slightly altered after 12
weeks of ICS therapy in 19 treated asthmatics (pZ 0.05).
Closed squares are geometric means and 95% confidence
intervals.
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measured indirectly using eNO, which is a well-established,
non-invasive method. Although eNO correlates with eosin-
ophilic inflammation27e29 and responds to ICS treat-
ment,16,30 it was not possible to draw conclusions from the
findings of the current study about the relationships
between airway distensibility and specific inflammatory
phenotypes.
We used treatment with ICS to determine if resolution of
steroid-responsive inflammation altered airway distensi-
bility. The treatment period of 12 weeks was expected to
effectively resolve steroid-responsive inflammation6 but
not to affect airway remodelling.5,6 The improvements in
FEV1, airway responsiveness, asthma control and eNO after
treatment are consistent with this. However, the
improvement in airway distensibility, which was of
borderline significance, suggests that airway distensibility,
measured by FOT, is partly influenced by steroid-responsive
inflammation. The precise mechanism of this is unclear but
it is likely that the steroid-responsive components of
inflammation, including oedema and plasma exudate
resulting from microvascular leakage,31,32 thicken theFigure 2 After treatment, airway distensibility and airway
responsiveness were unrelated (rZ0.31, pZ 0.20).airway walls thereby reducing airway distensibility. This is
supported by the results of imaging studies in which wall
thickness decreases with ICS.19 Alternatively there may be
direct effects of the inflammatory milieu on airway
mechanical properties.
It is important to note that despite the statistically
significant improvement, airway distensibility remained
abnormal after treatment. Furthermore, the mean (95%
CI) absolute increase in airway distensibility was only 0.06
(0.05) cm H2O s1, which is much less than the expected
day to day variation of 0.203 cmH2O s1.24 Similarly, the
changes for individual subjects were generally small, with
only one subject having an increase and two subjects
having decreases in airway distensibility that would be
regarded as clinically meaningful, i.e. greater than
0.203 cmH2O s1. These subjects had no systematic
similarities or differences in prior treatment, duration of
asthma, or any physiological characteristics that appear to
explain their relatively large changes in airway distensi-
bility with treatment. Since there was no correlation
between eNO and airway distensibility after treatment, we
propose that the remaining abnormalities in airway
distensibility are not due to airway inflammation and are
more likely due to the persistent effects of airway
remodelling.
There are other factors that potentially contribute to
reduced airway distensibility in asthmatics including
increased ASM tone, reduced lung elastic recoil, long
duration of disease and inflammation that is not responsive
to inhaled corticosteroid therapy. However, differences in
ASM tone and lung elastic recoil between asthmatics and
non-asthmatics do not account for the differences in
airway distensibility between the groups.24 Duration of
asthma has been associated with airway remodelling.33 In
our study, at baseline, duration of asthma was an inde-
pendent predictor of airway distensibility and together
with eNO accounted for 51% of the variance in airway
distensibility. Although there were no significant inde-
pendent predictors of airway distensibility after treat-
ment, duration of asthma accounted for 19% of the
variance in airway distensibility (pZ 0.06). This is consis-
tent with airway distensibility being a marker of airway
remodelling. The possible effects of steroid resistant
inflammation such as peribronchial inflammation on airway
distensibility are unknown.
The lack of association between airway responsiveness
and airway distensibility after short-term treatment
suggests that airway remodelling is not an important
determinant of AHR in asthma. Longer-term treatment
studies have shown that the biggest improvements in AHR
occur within the first few months with further incremental
improvements for up to 18 months.34,35 It is generally
assumed that the ongoing, long-term improvement in AHR is
due to a gradual reduction in airway remodelling. The
results of the current study do not contradict this hypoth-
esis but suggest that any potential contribution of airway
remodelling to AHR over the long term is likely to be small,
and therefore large sample sizes will be required to detect
any association.
We conclude that airway remodelling, as measured by
reduced airway distensibility, is unlikely to have either
a protective or detrimental effect on AHR in asthma.
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